• 20-80 yo KL≧II osteoarthritis patients

• VAS≧4, BMI 18-35 OA patients

• Complete cervical/thoracic SCI (ASIA A/B)

• Post-injury 1-12 months with normal renal/hepatic function

China Medical University Hospital uses autologous bone marrow mesenchymal stem cells (BM-MSCs) to treat two difficult diseases: knee osteoarthritis (KOA) and spinal cord injury (SCI). Knee treatment uses intra-articular injection with two doses per course (5×10⁷ cells/2ml) at 6-8 week intervals, unilateral or bilateral. SCI treatment uses intrathecal multi-dose injection combined with advanced MRI/fMRI imaging for quantitative assessment. Clinical data shows significant VAS and WOMAC improvement at 9 weeks, sustained to 12 months; MRI T2 mapping shows improved cartilage water content. KOA: 54 patients, 90 knees, zero SAE. SCI: 57.14% (4/7) ISNCSCI motor improvement (vs Korean trial 12.5%). One of few Taiwan teams with both indications, outperforming Spain, Australia, Korea benchmarks.

• Autologous BM-MSCs, low immune rejection

• High-cell-count multi-dose injection strategy

• Advanced MRI T2 mapping quantitative assessment

• Spinal/cerebral functional imaging for SCI

• Both KOA and SCI indications

• Few Taiwan teams with both indications

KOA (Knee Osteoarthritis) Service DataConsultation & Clinic Volume: [Awaiting your specific numbers]Enrollment & Screening: Successfully signed and enrolled 65 cases. Treatment & Completion: 56 cases (totaling 90 knees) entered and completed the full stem cell injection protocol. National Market Share: Autologous BM-MSC cases treated at CMUH account for up to 78% of the national total.

SCI (Spinal Cord Injury) Service DataConsultation & Clinic Volume: [Awaiting your specific numbers]Enrollment & Treatment: Successfully signed 11 cases, with 7 cases having undergone stem cell therapy. Completion Progress: 6 cases have successfully completed the entire cell therapy protocol.

KOA: 100% completion rate.

KOA: 100% execution rate.

KOA: 78% national market share.

KOA: Significant pain relief at 12 months.

SCI: 85.7% execution rate.

SCI: 1 case progressed from AIS Grade A to C. Safety: 0% infection rate.

Safety: 0 cases of serious adverse events (SAEs). Satisfaction: Overall patient satisfaction exceeds 98%.

KOA infection rate is 0%

SCI infection rate is 0%

serious adverse events :0

KOA adverse event rate is 7%

SCI adverse event rate is 0%

• Satisfaction: >98%

• Word-of-Mouth: Strong patient-to-patient recommendations

• Non-Surgical Relief: Achieved pain mitigation without surgery

• Quality of Life: Restored patients' daily living quality

• Outperforms Korean Neurosurgery SCI trial

• Better than Australia Freitag MOAKS team

• Better than Spain Lamo-Espinosa WOMAC team

• Advanced MRI assessment beyond traditional

• Manuscripts ready for journal submission

• Invited speaker at international stem cell forums

• Provides alternative to knee surgery

• Offers regenerative option for SCI patients

• Precision imaging enhances evidence level

• Foundation for future stem cell tendon/nerve reconstruction

• Advances domestic regenerative medicine industry